KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Asset Writedowns and Impairment: 2014-2023

Historic Asset Writedowns and Impairment for Jazz Pharmaceuticals (JAZZ) over the last 6 years, with Dec 2023 value amounting to $61.0 million.

  • Jazz Pharmaceuticals' Asset Writedowns and Impairment was N/A to $61.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $362.3 million, marking a year-over-year change of. This contributed to the annual value of $61.0 million for FY2023, which is 54.35% down from last year.
  • As of FY2023, Jazz Pharmaceuticals' Asset Writedowns and Impairment stood at $61.0 million, which was down 54.35% from $133.6 million recorded in FY2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Asset Writedowns and Impairment peaked at $136.1 million during FY2020, and registered a low of $61.0 million during FY2023.
  • In the last 2 years, Jazz Pharmaceuticals' Asset Writedowns and Impairment had a median value of $97.3 million in 2022 and averaged $97.3 million.
  • Data for Jazz Pharmaceuticals' Asset Writedowns and Impairment shows a maximum YoY crashed of 54.35% (in 2023) over the last 5 years.
  • Jazz Pharmaceuticals' Asset Writedowns and Impairment (Yearly) stood at $136.1 million in 2020, then reached $133.6 million in 2022, then plummeted by 54.35% to $61.0 million in 2023.